Regression of Electrocardiographic Left Ventricular Hypertrophy During Antihypertensive Therapy and Reduction in Sudden Cardiac Death: The LIFE Study

Background— Sudden cardiac death (SCD) occurs more often in patients with ECG left ventricular (LV) hypertrophy. However, whether LV hypertrophy regression is associated with a reduced risk of SCD remains unclear. Methods and Results— The Losartan Intervention for End Point Reduction in Hypertension (LIFE) study included 9193 patients 55 to 80 years of age with essential hypertension and ECG LV hypertrophy by gender-adjusted Cornell product (CP) (RaVL+SV3 [+6 mm in women]) · QRS duration>2440 mm · ms) and/or Sokolow-Lyon voltage (SLV) (SV1+RV5/6>38 mm). During follow-up (mean, 4.8 years), 190 patients (2%) experienced SCD. In time-dependent Cox analyses, absence of in-treatment LV hypertrophy was associated with a decreased risk of SCD: every 1-SD-lower in-treatment CP (1050 mm · ms) was associated with a 28% lower risk of SCD (hazard ratio [HR], 0.72; 95% CI, 0.66 to 0.79) and 1-SD-lower SLV (10.5 mm) with a 26% lower risk (HR, 0.74; 95% CI, 0.65 to 0.84). After adjustment for time-varying systolic and diastolic blood pressures, treatment allocation, age, gender, baseline Framingham risk score, ECG strain, heart rate, urine albumin/creatinine ratio, smoking, diabetes, congestive heart failure, coronary heart disease, atrial fibrillation, and occurrence of myocardial infarction, atrial fibrillation, heart failure, and noncardiovascular death, both in-treatment CP and SLV remained predictive of SCD: each 1-SD-lower CP was associated with a 19% lower risk of SCD (HR, 0.81; 95% CI, 0.73 to 0.90) and 1-SD-lower SLV with an 18% lower risk (HR, 0.82; 95% CI, 0.70 to 0.98). Absence of in-treatment LV hypertrophy by both SLV and CP was associated with a 30% lower risk of SCD (HR, 0.70; 95% CI, 0.54 to 0.92). Conclusions— Absence of in-treatment ECG LV hypertrophy is associated with reduced risk of SCD independently of treatment modality, blood pressure reduction, prevalent coronary heart disease, and other cardiovascular risk factors in hypertensive patients with LV hypertrophy.

[1]  M. Nieminen,et al.  Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. , 2004, JAMA.

[2]  M. Nieminen,et al.  Prognostic significance of left ventricular mass change during treatment of hypertension. , 2004, JAMA.

[3]  Hongwei Wang,et al.  Proportion of treatment effect (PTE) explained by a surrogate marker , 2003, Statistics in medicine.

[4]  M. Nieminen,et al.  Regression of Electrocardiographic Left Ventricular Hypertrophy by Losartan Versus Atenolol: The Losartan Intervention For Endpoint reduction in hypertension (LIFE) Study , 2003, Circulation.

[5]  M. Nieminen,et al.  Association of Left Ventricular Hypertrophy Regression and Heart Rate Reduction With Determinants of Myocardial Oxygen Consumption and Cardiovascular Events: The LIFE Study , 2003 .

[6]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[7]  Maurice Sokolow,et al.  American Heart Journal , 2001 .

[8]  P. Okin,et al.  Baseline Characteristics in Relation to Electrocardiographic Left Ventricular Hypertrophy in Hypertensive Patients: The Losartan Intervention For Endpoint Reduction (LIFE) in Hypertension Study , 2000, Hypertension.

[9]  M. Nieminen,et al.  Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. , 1998, Hypertension.

[10]  D. Levy,et al.  Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. , 1998, Journal of the American College of Cardiology.

[11]  M. Nieminen,et al.  The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. , 1997, American journal of hypertension.

[12]  G. Schillaci,et al.  Association between persistent pressure overload and ventricular arrhythmias in essential hypertension. , 1996, Hypertension.

[13]  P Kligfield,et al.  Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. , 1995, Journal of the American College of Cardiology.

[14]  P Kligfield,et al.  Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage-duration product. , 1992, Journal of the American College of Cardiology.

[15]  W. Kannel,et al.  Long- and short-term risk of sudden coronary death. , 1992, Circulation.

[16]  J. Laragh,et al.  Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. , 1991, Annals of internal medicine.

[17]  K. Anderson,et al.  An updated coronary risk profile. A statement for health professionals. , 1991, Circulation.

[18]  N. Kaplan.  Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. , 1988, The New England journal of medicine.

[19]  D. Levy,et al.  Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. , 1987, The American journal of cardiology.

[20]  W. Kannel,et al.  A prognostic comparison of asymptomatic left ventricular hypertrophy and unrecognized myocardial infarction: the Framingham Study. , 1986, American heart journal.

[21]  W. Kannel,et al.  Sudden death: lessons from subsets in population studies. , 1985, Journal of the American College of Cardiology.

[22]  F. Epstein,et al.  Predisposing Factors in Sudden Cardiac Death in Tecumseh, Michigan: A Prospective Study , 1970, Circulation.

[23]  M. Sokolow,et al.  The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. , 1949, American heart journal.